Develop and test methods for the standardization of immunoassays and mass-spectrometry/single reaction monitoring assay or other methodologies for CSF abeta & tau and other biomarkers as they become clinically applicable. Develop and test methods for standardization of collection and analysis of MRI and PET neuroimaging data.
CLIA laboratory qualification in US & the equivalent certification in the EU for at least one CSF biomarker of disease pathology. For neuroimaging data, qualification of at least one biomarker for use in clinical trials by the FDA and/or the EMA.
2014 to 2019
Research Implementation Area
B. Diagnosis, Assessment and Disease Monitoring